Flow Cytometry Market

Flow Cytometry Market Size, Share & Trends

The size of global flow cytometry market in terms of revenue was estimated to be worth $5.1 billion in 2024 and is poised to reach $10.3 billion by 2032, growing at a CAGR of 9.2% from 2024 to 2032. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

The major factors driving the flow cytometry growth are advancements in technology, increasing adoption in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine. Additionally, the integration of AI and machine learning is enhancing data analysis capabilities, further fueling market growth.

Flow Cytometry Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Global Flow cytometry market Dynamics

Driver: Launch of technologically advanced flow cytometry products

Players operating in the global flow cytometry market are increasingly focused on developing and commercializing technologically advanced flow cytometry products that offer streamlined workflows, ease of operability, and improved turnaround times. Continuous innovations in flow cytometry instruments, such as the development of multiplexing capabilities, higher throughput systems, and enhanced data analysis software, also drive market growth. These advancements improve the efficiency, sensitivity, and accuracy of flow cytometry assays, making them more attractive for research and clinical applications. For instance, in April 2024, Becton, Dickinson and Company (US) introduced BD FACSDiscover S8 Cell Sorter, which features BD CellView Image Technology and BD SpectralFX Technology; these new spectral cell sorters offer real-time imaging and spectral flow cytometry capabilities.

Restraint: High cost of instruments

Most end users, such as clinical laboratories, large research facilities, and pharmaceutical companies, require many flow cytometry instruments to conduct multiple research studies simultaneously. This leads to a significant increase in the capital cost associated with the procurement and maintenance of these devices. Due to restricted budgets, academic & research laboratories find it difficult to afford such instruments. The high cost of flow cytometry instruments and consumables poses a significant barrier to their adoption, particularly for smaller research laboratories and healthcare facilities with limited budgets. Additionally, maintenance cost of instruments and other indirect expenses adds on to the overall cost of the intrument. Thus, elevated product install cost and related overheads is likely to hinder implementation of flow cytometry instruments in clinical and research facilities, specifically in emerging countries. In addition, these instruments are equipped with advanced features and functionalities, thus making them high-priced instruments. However, flow cytometry-based cell sorters are more expensive than cell analyzers. For instance, as of January 2024 (published in Excedr), the average cost of a flow cytometer varies between USD 100,000 and more than USD 500,000 for a single unit.

Opportunity: Increased use in clinical applications and infectious disease diagnostics

The expansion of flow cytometry procedures in clinical diagnostics offers a significant growth opportunity for the market. Flow cytometry's ability to analyze cellular characteristics and biomarkers has led to its increasing utilization in clinical laboratories for disease diagnosis, prognosis, and monitoring. For instance, in hematology, flow cytometry is widely used for diagnosing and monitoring hematological malignancies, such as leukemia and lymphoma, by analyzing the expression patterns of cell surface markers. Similarly, in immunology, flow cytometry plays a critical role in diagnosing immunodeficiencies and autoimmune disorders by assessing immune cell populations and their functional status. The expansion of flow cytometry in clinical diagnostics is driven by factors such as advancements in instrumentation, automation, assay development, and the recognition of flow cytometry as a valuable tool in precision medicine. For instance, in March 2024, Beckman Coulter received the USFDA 510(k) clearance for its DxFLEX Clinical Flow Cytometer; it is validated as an IVD device for 10-color immunophenotyping with the ClearLLab 10C reagent system and delivers the only FDA-cleared and CE marked integrated leukemia and lymphoma solution.

Challenge: Complexities related to reagent development

The complexities associated with reagent development present a notable challenge to the growth of the flow cytometry market. Reagents, including fluorescently labeled antibodies and dyes, are essential components of flow cytometry assays, which help identify and analyze specific cellular markers. However, developing high-quality reagents with optimal specificity, sensitivity, and stability can be a time-consuming and resource-intensive process. For example, the selection and validation of antibodies for flow cytometry require extensive testing to ensure they bind specifically to their target antigens without cross-reactivity. Additionally, reagents must be validated for compatibility with different sample types, staining protocols, and instrument configurations to ensure reproducible results across diverse applications and laboratory settings.

Ecosystem Analysis Flow Cytometry Market

The reagents & consumables segment dominated the flow cytometry industry in 2023.

Based on product & service, the flow cytometry market is segmented into services, software, reagents & consumables, instruments, and accessories. The reagents & consumables segment is further divided into antibodies, assays & kits and other reagents & consumables. The reagents & consumables segment dominanted the market owing to various factors such as adavncements in regents, increased research & development activites and adoption of flow cytometry for clinical appplications.

The academic & research institutes is poised to exhibit substantial growth at a significant CAGR throughout the flow cytometry industry forecast period.

On the basis of end user, the flow cytometry market is segmented into academic & research institutes hospitals & clinical testing laboratories,  and pharmaceutical & biotechnology companies. In 2023, academic & research institute segment dominanted the end user segment. Increased investment in clinical trials, drug development, and biopharmaceutical research is likely to cointribute towards growth of the academic & research institute segment. Furthermore, demand for advanced technologies and high-throughput capabilities drives market growth, supported by significant funding and grants for scientific research.

North America dominated global flow cytometry industry in 2023.

There are six main regional segmentations for the flow cytometry market North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. In 2023, North America dominated the flow cytometry market followed by Europe. North America's dominance in the flow cytometry market is attributed to robust healthcare infrastructure, significant investment in research and development, and high adoption of advanced technologies. The presence of leading market players, extensive clinical research activities, and favorable regulatory policies further bolster the region's leading position in flow cytometry market.

Asia Pacific region is likely to grow at significant CAGR during the forecast period of 2024-2032. The growing prevalence of chronic diseases, rising healthcare expenditure, and supportive government initiatives are driving the adoption of flow cytometry technologies across various applications, fueling market expansion in the region.

To know about the assumptions considered for the study, download the pdf brochure

Source: Expert Interviews, Secondary Research, Whitepapers, Journals, Magazines, and MarketsandMarkets Analysis

Key players in the flow cytometry market include Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Sony Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Miltenyi Biotec (Germany), Enzo Biochem, Inc. (US), Sysmex Corporation (Japan), bioMérieux (France), Cytonome/ST, LLC (US), Sartorius AG (Germany) and Cytek Biosciences (US) among others.

Scope of the Flow Cytometry Industry:

This report categorizes the flow cytometry market into the following segments and subsegments:

By Technology

• Cell-based Flow Cytometry
• Bead-based Flow Cytometry

By Product and Service

• Reagents and Consumables
  • Antibodies
  • Assays & Kits
  • Other Reagents & Consumables
• Instruments
  • Cell Analyzers
    • High-range
    • Mid-range
    • Low-range
  • Cell Sorters
    • High-range
    • Mid-range
    • Low-range
• Services
• Software
• Accessories

By Application

• Research Applications
  • Pharmaceuticals and Biotechnology
    • Drug Discovery
    • Stem Cell Research
    • In Vitro Toxicity Testing
  • Immunology
  • Cell Sorting
  • Apoptosis
  • Cell Cycle Analysis
  • Cell Viability
  • Cell Counting
  • Other Research Applications
• Clinical Applications
  • Cancer Diagnostics
  • Hematology
  • Autoimmune Diseases
  • Organ Transplantation
  • Other Clinical Applications
• Industrial Applications

By End User

• Academic & Research Institutes
• Hospitals & Clinical Testing Laboratories
• Pharmaceutical & Biotechnology Companies

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Indonesia
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East
  • GCC Countries
    • KSA (Saudi Arabia)
    • UAE (United Arab Emirates)
    • Rest of GCC Countries
    •  
  • Rest of Middle East
• Africa

Recent Developments of the Flow Cytometry Industry:

• In May 2024, Agilent Technologies Inc. launched NovoCyte Opteon Spectral Flow Cytometer with with configurations ranging from three to five lasers and support for up to 73 high-quality detectors.
• In March 2024, Beckman Coulter introduced CytoFLEX nano Flow Cytometer.The instruments offers simultaneous multiparameter detection powered by six fluorescent detection channels and five side scatter channels.
• In October 2023, Sony Corporation launched FP7000 spectral cell sorter that supports high-speed, high-parameter sorting with more than 44 colors with simple workflows, leveraging its patented spectral technology-based optics, advanced electronics and fluidics.
• In March 2023, BD (Becton, Dickinson and Company) launched BD FACSDiscover S8 Cell Sorter is first world’s spectral cell sorter with high-speed cell imaging.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst